Analogs of Luteinizing Hormone-releasing Hormone in Benign Prostatic Hyperplasia and Advanced Renal Cell Carcinoma

  • A. M. Comaru-Schally
Conference paper


Benign prostatic hyperplasia (BPH) is a significant health problem all over the world. This condition will affect most men should they live long enough and can lead to serious complications, such as acute or chronic urinary retention, renal insufficiency, urinary tract infection and sexual dysfunction (Oesterling, 1996; Isaacs, 1990). Symptomatic BPH causes morbidity and can lower the quality of life (QoL) (Hoznek and Abben, 2001; Hegarty et al., 2001). We investigated whether short-term administration of the LHRH antagonist cetrorelix could provide a new treatment for men with BPH (Comaru-Schally et al., 1998).


Renal Cell Carcinoma Benign Prostatic Hyperplasia Sexual Function International Prostate Symptom Score Urinary Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aoyagi T., Takishima K., Hayakawa M. and Nakamura H. (1996). Gene expression of TGF-α, EGF and IL-6 in cultured renal tubular cells and renal cell carcinoma. Int J Urol, 3, 392–396.PubMedCrossRefGoogle Scholar
  2. Barry M. and Roehrborn C. (1997). Management of benign prostatic hyperplasia. Annu Rev Med, 48, 177–189.PubMedCrossRefGoogle Scholar
  3. Begun F.R, Story M.T., Hopp K.A., Shapiro E. and Lawson R.K. (1995). Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostates. J Urol, 153, 839–843.PubMedCrossRefGoogle Scholar
  4. Cohen P., Peehl D.M., Baker B., Liu F., Hintz R.L. and Rosenfeld R.G. (1994). Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab, 79, 1410–1415.PubMedCrossRefGoogle Scholar
  5. Comaru-Schally A.M., Brannan W., Schally A.V., Colcolough M. and Monga M. (1998). Efficacy and safety of LHRH antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab, 83, 3826–3831.PubMedCrossRefGoogle Scholar
  6. Culig Z., Hobisch A., Cronauer M.V., Radmayr C, Hittmair A., Zhang J., Thurnher M., Bartsch G. and Klocker H. (1996). Regulation of prostatic growth and function by peptide growth factors. Prostate, 28, 392–405.PubMedCrossRefGoogle Scholar
  7. De Bellis A., Ghiandi P., Comerci A., Fiorelli G., Grappone C, Milani S., Salerno R., Marra F. and Serio M. (1996). Epidermal growth factor, epidermal growth factor receptor, and transforming growth factor-alpha in human hyperplastic prostate tissue: expression and cellular localization. J Clin Endocrinol Metab, 81, 4148–4154.PubMedCrossRefGoogle Scholar
  8. Dutcher J.P., Fisher R.I., Weiss G., Aronson E, Margolin K., Louie A., Mier J., Caliendo G., Sosman J.A., Eckardt J.R., Ernest M.L., Doroshow J. and Atkins M. (1997). Outpatient subcutaneous interleukin-2 and interferon-α for metastatic renal cell cancer: 5-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am, 3, 157–162.PubMedGoogle Scholar
  9. Gabrilove J.L., Levine A.C., Kirschenbaum A., Droller M. (1989). Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy. J Clin Endocrinol Metab, 69, 629–632.PubMedCrossRefGoogle Scholar
  10. Godley P. and Kim S.W. (2002). Renal cell carcinoma. Curr Opin Oncol, 14, 280–285.PubMedCrossRefGoogle Scholar
  11. Gonzalez-Barcena D., Vadillo-Buenfil M., Gomez-Orta F., Fuentes Garcia M., Cardenas-Cornejo I., Graef-Sanchez A., Comaru-Schally A.M. and Schally A.V. (1994). Responses to the antagonistic analog of LHRH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate, 24, 84–92.PubMedCrossRefGoogle Scholar
  12. Hegarty P.K., Hegarty N.J., Fitzpatrick J.M. (2001). Sexual function in patients with benign prostatic hyperplasia. Curr Urol Rep, 2, 292–296.PubMedCrossRefGoogle Scholar
  13. Henriksson R., Nilsson S., Colleen S., Wersau P., Heising M., Zimmerman R. and Engman K. (1998). Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs. interleukin 2, a-interferon (leucocyte) and tamoxifen. Br J Cancer, 77, 1311–1317.PubMedCrossRefGoogle Scholar
  14. Hoznek A. and Abbou C.C. (2001). Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function. Curr Urol Rep, 2, 311–317.PubMedCrossRefGoogle Scholar
  15. Isaacs J.T. (1990). Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate, 3, 1–7.PubMedCrossRefGoogle Scholar
  16. Jemal A., Thomas A., Murray T. and Thun M. Cancer statistics. (2002). CA Cancer J Clin, 52, 23–47.PubMedCrossRefGoogle Scholar
  17. Jungwirth A., Schally A.V., Haimos G., Groot K., Szepeshazi K., Pinski J. and Armatis P. (1998). Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by LHRH antagonists Cetrorelix, somatostatin analog RC-160 and bombesin antagonist RC-3940-II. Cancer, 82, 909–917.PubMedCrossRefGoogle Scholar
  18. Lepor H., Williford W.O., Barry M.J., Brawer M.K., Dixon CM., Gormley G., Haakenson C, Machi M., Narayan P. and Padley R.J. (1996). The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med, 335, 533–539.PubMedCrossRefGoogle Scholar
  19. McKiernan J.M. and Lowe F.C. (1997). Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. South Med J, 90, 509–513.PubMedCrossRefGoogle Scholar
  20. Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma. N Engl J Med, 1996, 335, 865–875.PubMedCrossRefGoogle Scholar
  21. Nickel J.C., Fradet Y., Boake R.C., Pommerville P.J., Perreault J.P., Afridi S.K. and Elhilali M.M. (1996). Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Can Med Assoc J, 155,1251–1259.Google Scholar
  22. Oesterling J.E. (1996). Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate, 6, 67–73.PubMedCrossRefGoogle Scholar
  23. Papadopoulos I., Rudolph P., Weichert-Jacobsen K., Thiemann O. and Papadopoulou D. (1996). Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon-α2β and vinblastine. Urology, 48, 373–378.PubMedCrossRefGoogle Scholar
  24. Peters C.A. and Walsh P.C. (1987). The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med, 317, 599–604.PubMedCrossRefGoogle Scholar
  25. Reynolds C.F. III, Frank E., Thase M.E., Houck P.R., Jennings J.R., Howell J.R., Lilienfeld S.O. and Kupfer D.J. (1988). Assessment of sexual function in depressed, impotent, and healthy men: factor analysis of a Brief Sexual Function Questionnaire for men. Psychiat Res, 24, 231–250.CrossRefGoogle Scholar
  26. Richie J.P., Kantoff P.W. and Shapiro C.L. (1997). Renal cell carcinoma. In Cancer Medicine, 4th edn, eds, Holland J.F., Frei E. III, Bast R.C Jr, Kufe D.W., Morton D.L. and Weichselbaum R.R., pp. 2085–2096. Baltimore, MD, Williams & Wilkins.Google Scholar
  27. Schally A.V. and Comaru-Schally A.M. (1997a). Hypothalamic and other peptide hormones. In Cancer Medicine, 4th edn, eds, Holland J.F., Frei E. III, Bast R.C Jr, Kufe D.W., Morton D.L. and Weichselbaum R.R., pp. 1067-1086. Baltimore, MD, Williams & Wilkins.Google Scholar
  28. Schally A.V. and Comaru-Schally A.M. (1997b). Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LHRH) in the treatment of hormone-sensitive neoplasms and gynecologic conditions. Adv Drug Deliv Rev, 28, 157–169.CrossRefGoogle Scholar
  29. Schally A.V. and Comaru-Schally A.M. (2000). Hypothalamic and other peptide hormones. In Cancer Medicine, 4th edn, eds, Holland J.F., Frei E. III, Bast R.C. Jr, Kufe D.W., Morton D.L. and Weichselbaum R.R., pp.715–729 Hamilton, Ontario, B.C. Dekker.Google Scholar
  30. Schally A.V., Comaru-Schally A.M., Nagy A., Kovacs M., Szepeshazi K., Plonowski A., Varga J.L. and Haimos G. (2001). Hypothalamic Hormones and cancer. Front Neuroendocrinol, 22, 248–291.PubMedCrossRefGoogle Scholar
  31. Shapiro E. and Lepor H. (1995). Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am, 22, 285–290.PubMedGoogle Scholar
  32. Sion-Vardi N., Kaneti J., Segal-Abramson T., Giat J., Levy J. and Sharoni Y. (1992). Gonadotropin-releasing hormone specific binding sites in normal and malignant renal tissue. J Urol, 148, 1568–1570.PubMedGoogle Scholar
  33. Sokoloff M.H., deKernion J.B., Figlin R.A. and Belldegrun A. (1996). Current management of renal cell carcinoma. CA Cancer J Clin, 46, 284–302.PubMedCrossRefGoogle Scholar
  34. Steiner M.S. (1995). Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol, 153, 1085–1096.PubMedCrossRefGoogle Scholar
  35. Wise G.J. and Ostad E. (2001). Hormonal treatment of patients with benign prostatic hyperplasia: pros and cons. Curr Urol Rep, 2, 285–291.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • A. M. Comaru-Schally

There are no affiliations available

Personalised recommendations